MX2018011194A - 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj). - Google Patents
6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj).Info
- Publication number
- MX2018011194A MX2018011194A MX2018011194A MX2018011194A MX2018011194A MX 2018011194 A MX2018011194 A MX 2018011194A MX 2018011194 A MX2018011194 A MX 2018011194A MX 2018011194 A MX2018011194 A MX 2018011194A MX 2018011194 A MX2018011194 A MX 2018011194A
- Authority
- MX
- Mexico
- Prior art keywords
- dihydropyrimidine
- carboxamides
- oxo
- hydroxy
- apj agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula (I): (ver Fórmula) en donde todas las variables son como se definen en la descripción, y composiciones que comprenden cualquiera de tales compuestos novedosos. Estos compuestos son agonistas de APJ que se pueden usar como medicamentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662312780P | 2016-03-24 | 2016-03-24 | |
PCT/US2017/023801 WO2017165640A1 (en) | 2016-03-24 | 2017-03-23 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018011194A true MX2018011194A (es) | 2019-01-10 |
Family
ID=58464691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018011194A MX2018011194A (es) | 2016-03-24 | 2017-03-23 | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj). |
Country Status (22)
Country | Link |
---|---|
US (2) | US10106528B2 (es) |
EP (1) | EP3433247B1 (es) |
JP (1) | JP6716711B2 (es) |
KR (1) | KR102433280B1 (es) |
CN (1) | CN109195963B (es) |
AR (1) | AR107973A1 (es) |
AU (1) | AU2017238504B2 (es) |
BR (1) | BR112018068341A2 (es) |
CA (1) | CA3018346A1 (es) |
CL (1) | CL2018002671A1 (es) |
CO (1) | CO2018011105A2 (es) |
EA (1) | EA037162B1 (es) |
ES (1) | ES2895124T3 (es) |
IL (1) | IL261904B (es) |
MA (1) | MA43761A (es) |
MX (1) | MX2018011194A (es) |
MY (1) | MY189454A (es) |
SG (1) | SG11201808163WA (es) |
TW (1) | TWI744301B (es) |
UY (1) | UY37169A (es) |
WO (1) | WO2017165640A1 (es) |
ZA (1) | ZA201806356B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI672299B (zh) | 2015-06-03 | 2019-09-21 | 美商必治妥美雅史谷比公司 | 4-羥基-3-(雜芳基)吡啶-2-酮apj促效劑 |
US10392347B2 (en) | 2015-10-14 | 2019-08-27 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as APJ agonists |
CA3007280A1 (en) | 2015-12-04 | 2017-06-08 | Bristol-Myers Squibb Company | Apelin receptor agonists and methods of use |
WO2017106396A1 (en) | 2015-12-16 | 2017-06-22 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
AU2017238504B2 (en) * | 2016-03-24 | 2021-05-27 | Bristol-Myers Squibb Company | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists |
WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
CN109641843B (zh) | 2016-06-14 | 2022-07-19 | 百时美施贵宝公司 | 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮 |
WO2017218633A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists |
WO2018071622A1 (en) | 2016-10-14 | 2018-04-19 | Bristol-Myers Squibb Company | 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists |
US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
EP3541804A1 (en) | 2016-11-16 | 2019-09-25 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
EP3541805B1 (en) | 2016-11-16 | 2020-10-14 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
US11807624B2 (en) | 2018-05-01 | 2023-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the APJ receptor |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH602664A5 (en) * | 1973-06-14 | 1978-07-31 | Sandoz Ag | 2-Tert. amino-alkylamino-pyrimidine derivs. |
GB2263639A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
CA2258949C (en) | 1996-07-01 | 2008-05-06 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
EP1301490A2 (en) | 2000-07-18 | 2003-04-16 | Neurogen Corporation | 5-substituted 2-aryl-4-pyrimidinones |
TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
MXPA04011074A (es) | 2002-05-09 | 2005-06-08 | Cytokinetics Inc | Compuestos de pirimidinona, composiciones y metodos. |
AU2003231799A1 (en) | 2002-05-23 | 2003-12-12 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
JP2004339159A (ja) | 2003-05-16 | 2004-12-02 | Sankyo Co Ltd | 4−オキソキノリン誘導体を含有する医薬組成物 |
US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005041888A2 (en) | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
EP1697331A4 (en) | 2003-12-19 | 2010-08-04 | Merck Sharp & Dohme | INHIBITORS OF MITOTIC KINESINE |
WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007037543A1 (ja) | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | ビアリールアミド誘導体 |
WO2007064797A2 (en) | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
EP2016056A4 (en) | 2006-04-21 | 2010-11-10 | Univ Boston | IONIC VISCOELASTIC AND VISCOELASTIC SALTS |
WO2008052861A2 (de) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten |
WO2008052863A2 (de) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Verfahren zur umsetzung von 1,3-hetero-aromatischen 2-carboxylaten mit wasser |
TW200845994A (en) * | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
US8415321B2 (en) | 2008-04-15 | 2013-04-09 | Raymond F. Schinazi | Nucleoside derivatives for treatment of Caliciviridae infections, including Norovirus infections |
WO2010072696A2 (de) | 2008-12-22 | 2010-07-01 | Basf Se | Mischungen hydrophober und hydrophiler ionischer flüssigkeiten und ihre verwendung in flüssigkeitsringverdichtern |
TW201100411A (en) | 2009-05-21 | 2011-01-01 | Chlorion Pharma Inc | Pyrimidines as novel therapeutic agents |
EP2604260B1 (en) | 2010-08-10 | 2017-05-10 | Shionogi&Co., Ltd. | Novel heterocyclic derivatives and pharmaceutical composition containing same |
JP5990262B2 (ja) | 2011-05-31 | 2016-09-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | ヒドリド−トリシアノ−ボラートアニオンを含む化合物 |
KR20140039242A (ko) | 2011-05-31 | 2014-04-01 | 메르크 파텐트 게엠베하 | 전해질 제형 |
WO2014004676A1 (en) | 2012-06-26 | 2014-01-03 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors as neuroprotective agents in the cns |
DE102012021452A1 (de) | 2012-10-31 | 2014-04-30 | Merck Patent Gmbh | Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion |
KR20150135332A (ko) | 2013-03-14 | 2015-12-02 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법 |
MX2020013099A (es) | 2013-06-27 | 2022-07-26 | Pfizer | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina. |
WO2014207100A1 (en) | 2013-06-27 | 2014-12-31 | Basf Se | A process for coating paper with cellulose using a solution containing cellulose |
CN106029804B (zh) | 2013-11-29 | 2019-09-24 | 普罗奥尼克股份有限公司 | 使用微波辐射使粘合剂固化的方法 |
US10570128B2 (en) * | 2014-05-28 | 2020-02-25 | Sanford Burnham Prebys Medical Discovery Institute | Agonists of the apelin receptor and methods of use thereof |
US10377718B2 (en) * | 2014-06-06 | 2019-08-13 | Research Triangle Institute | Apelin receptor (APJ) agonists and uses thereof |
WO2016074757A1 (de) | 2014-11-11 | 2016-05-19 | Merck Patent Gmbh | Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren |
US10774051B2 (en) | 2015-04-24 | 2020-09-15 | Shionogi & Co., Ltd. | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same |
UA119932C2 (uk) | 2015-05-20 | 2019-08-27 | Емджен Інк. | Триазолові агоністи рецептора apj |
TWI672299B (zh) * | 2015-06-03 | 2019-09-21 | 美商必治妥美雅史谷比公司 | 4-羥基-3-(雜芳基)吡啶-2-酮apj促效劑 |
KR101711744B1 (ko) | 2015-07-16 | 2017-03-02 | 경희대학교 산학협력단 | 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층 |
US10392347B2 (en) | 2015-10-14 | 2019-08-27 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as APJ agonists |
EP3380970B1 (en) | 2015-11-24 | 2023-01-04 | Sanford Burnham Prebys Medical Discovery Institute | Novel azole derivatives as apelin receptor agonist |
CA3007280A1 (en) | 2015-12-04 | 2017-06-08 | Bristol-Myers Squibb Company | Apelin receptor agonists and methods of use |
WO2017106396A1 (en) | 2015-12-16 | 2017-06-22 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
AU2017238504B2 (en) * | 2016-03-24 | 2021-05-27 | Bristol-Myers Squibb Company | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists |
WO2017218633A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists |
CN109641843B (zh) | 2016-06-14 | 2022-07-19 | 百时美施贵宝公司 | 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮 |
-
2017
- 2017-03-23 AU AU2017238504A patent/AU2017238504B2/en not_active Ceased
- 2017-03-23 TW TW106109801A patent/TWI744301B/zh not_active IP Right Cessation
- 2017-03-23 CN CN201780031787.XA patent/CN109195963B/zh active Active
- 2017-03-23 AR ARP170100736A patent/AR107973A1/es unknown
- 2017-03-23 MA MA043761A patent/MA43761A/fr unknown
- 2017-03-23 EA EA201892123A patent/EA037162B1/ru not_active IP Right Cessation
- 2017-03-23 EP EP17715361.6A patent/EP3433247B1/en active Active
- 2017-03-23 KR KR1020187030255A patent/KR102433280B1/ko active IP Right Grant
- 2017-03-23 MY MYPI2018703358A patent/MY189454A/en unknown
- 2017-03-23 JP JP2018549910A patent/JP6716711B2/ja active Active
- 2017-03-23 CA CA3018346A patent/CA3018346A1/en active Pending
- 2017-03-23 BR BR112018068341A patent/BR112018068341A2/pt not_active Application Discontinuation
- 2017-03-23 WO PCT/US2017/023801 patent/WO2017165640A1/en active Application Filing
- 2017-03-23 ES ES17715361T patent/ES2895124T3/es active Active
- 2017-03-23 SG SG11201808163WA patent/SG11201808163WA/en unknown
- 2017-03-23 MX MX2018011194A patent/MX2018011194A/es unknown
- 2017-03-24 UY UY0001037169A patent/UY37169A/es unknown
- 2017-03-24 US US15/468,230 patent/US10106528B2/en active Active
-
2018
- 2018-09-06 US US16/122,975 patent/US10590113B2/en active Active
- 2018-09-20 IL IL261904A patent/IL261904B/en active IP Right Grant
- 2018-09-21 CL CL2018002671A patent/CL2018002671A1/es unknown
- 2018-09-21 ZA ZA2018/06356A patent/ZA201806356B/en unknown
- 2018-10-17 CO CONC2018/0011105A patent/CO2018011105A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EA201892123A1 (ru) | 2019-02-28 |
TWI744301B (zh) | 2021-11-01 |
US10106528B2 (en) | 2018-10-23 |
CO2018011105A2 (es) | 2018-10-22 |
AR107973A1 (es) | 2018-07-04 |
MY189454A (en) | 2022-02-14 |
JP2019509319A (ja) | 2019-04-04 |
US20190002441A1 (en) | 2019-01-03 |
BR112018068341A2 (pt) | 2019-01-15 |
UY37169A (es) | 2017-09-29 |
IL261904A (en) | 2018-10-31 |
SG11201808163WA (en) | 2018-10-30 |
WO2017165640A1 (en) | 2017-09-28 |
CN109195963A (zh) | 2019-01-11 |
EA037162B1 (ru) | 2021-02-12 |
JP6716711B2 (ja) | 2020-07-01 |
TW201736362A (zh) | 2017-10-16 |
EP3433247B1 (en) | 2021-09-08 |
KR102433280B1 (ko) | 2022-08-17 |
KR20180129836A (ko) | 2018-12-05 |
CA3018346A1 (en) | 2017-09-28 |
CN109195963B (zh) | 2021-04-23 |
MA43761A (fr) | 2021-05-05 |
CL2018002671A1 (es) | 2019-01-25 |
IL261904B (en) | 2020-09-30 |
AU2017238504A1 (en) | 2018-11-15 |
US10590113B2 (en) | 2020-03-17 |
ZA201806356B (en) | 2021-05-26 |
AU2017238504B2 (en) | 2021-05-27 |
ES2895124T3 (es) | 2022-02-17 |
EP3433247A1 (en) | 2019-01-30 |
US20170275272A1 (en) | 2017-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018011194A (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj). | |
MX2018004344A (es) | 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj). | |
MX2018006217A (es) | Agonistas del receptor de apelina y metodos de uso. | |
PH12017502158A1 (en) | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders | |
MX2018007155A (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj). | |
MX2018015247A (es) | Heterociclos de biarilmetilo. | |
PH12017500660A1 (en) | Novel compositions, uses and methods for making them | |
MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
PH12018500408A1 (en) | Bicyclic compounds as atx inhibitors | |
MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
EA201691916A1 (ru) | Биарильные ингибиторы киназы | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
NZ763528A (en) | Heterocyclic gpr119 agonist compounds | |
MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
MX2017008390A (es) | Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato. | |
TN2018000057A1 (en) | Compounds useful for inhibiting ror-gamma-t. | |
EA201691549A1 (ru) | Ариллактамные ингибиторы киназы | |
MX2017011116A (es) | Composiciones novedosas, usos y metodos para hacerlas. | |
MX2019008375A (es) | Tiobenzoimidazol como fungicidas. | |
PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs | |
EA202090835A1 (ru) | Композиции, содержащие бактериальные штаммы | |
PH12018500406A1 (en) | Bicyclic compounds as atx inhibitors |